<DOC>
	<DOC>NCT02619994</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy of a 'new treatment regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for nine or twelve months (investigational arm)' and 'the standard treatment regimen including injectables for 20 to 24 months (control arm)' for treating quinolone sensitive multidrug-resistant tuberculosis.</brief_summary>
	<brief_title>Treatment Shortening of MDR-TB Using Existing and New Drugs</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Males and females aged from 19 to 85 years Confirmed Rifampicin resistance On current TB therapy for ≤14 days at the time of enrollment. Known any quinoloneresistant MDRTB patients Known XDRTB patients Patients who are pregnant or who are unwilling to use proper contraceptives at childbearing age Medical history of galactose intolerance, Lapp lactase deficiency, glucosegalactose malabsorption The need for ongoing use of prohibited drugs while on study drugs History of optic neuropathy or peripheral neuropathy People with any of the following test results: i.Absolute neutrophil count &lt; 2000 cells/mL, ii.White blood cell count (WBC) &lt; 3.0 X 103/µL, iii.Hemoglobin &lt; 7.0 g/dL, iv.Serum creatinine &gt; 2.0 mg/dL, v.Aspartate aminotransferase (AST or SGOT) &gt;100 IU/L, vi.Alanine aminotransferase (ALT or SGPT) &gt;100 IU/L, vii.Total bilirubin &gt; 2.0 mg/dL, viii.Albumin &lt; 2.8g/dL, ix.QTcF &gt; 500ms History of hypersensitivity reaction to the study drugs</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>MDR tuberculosis</keyword>
	<keyword>linezolid</keyword>
	<keyword>delamanid</keyword>
	<keyword>Korea</keyword>
</DOC>